Biomerica (NASDAQ:BMRA) Share Price Passes Below 200-Day Moving Average – Here’s Why

Biomerica, Inc. (NASDAQ:BMRA) shares passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.34 and traded as low as $2.73. Biomerica shares last traded at $2.80, with a volume of 24,879 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Biomerica in a research report on Saturday, September 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Biomerica Price Performance

The stock has a 50 day simple moving average of $3.00 and a 200-day simple moving average of $3.34. The firm has a market cap of $8.04 million, a PE ratio of -1.21 and a beta of 0.34.

Institutional Trading of Biomerica

A hedge fund recently bought a new stake in Biomerica stock. Bulltick Wealth Management LLC bought a new position in Biomerica, Inc. (NASDAQ:BMRA) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 137,149 shares of the company’s stock, valued at approximately $78,000. Bulltick Wealth Management LLC owned approximately 5.39% of Biomerica at the end of the most recent quarter. 22.28% of the stock is currently owned by institutional investors and hedge funds.

About Biomerica

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.